Identification

Name
Palbociclib
Accession Number
DB09073
Type
Small Molecule
Groups
Approved
Description

Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6 indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein. Inhibition of these proteins leads to reduced phosphorylation of Rb, inhibition of downstream signalling, and increased tumor growth arrest. Palbociclib received an accelerated approval from the Food and Drug Administration on February 3, 2015.

Structure
Thumb
Synonyms
  • 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
External IDs
PD 0332991 / PD 332991 / PD-0332991 / PD-332991 / PD0332991 / PD332991 / UNII-G9ZF61LE7G
Product Ingredients
IngredientUNIICASInChI Key
Palbociclib IsethionateW1NYL2IRDR827022-33-3LYYVFHRFIJKPOV-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IbranceCapsule125 mg/1OralU.S. Pharmaceuticals2015-02-03Not applicableUs
IbranceCapsule125 mgOralPfizer2016-04-19Not applicableCanada
IbranceCapsule125 mg/1OralPfizer Laboratories Div Pfizer Inc.2015-02-03Not applicableUs
IbranceCapsule75 mgOralPfizer2016-04-20Not applicableCanada
IbranceCapsule75 mg/1OralPfizer Laboratories Div Pfizer Inc.2015-02-03Not applicableUs
IbranceCapsule100 mgOralPfizer2016-04-19Not applicableCanada
IbranceCapsule100 mg/1OralPfizer Laboratories Div Pfizer Inc.2015-02-03Not applicableUs
Categories
UNII
G9ZF61LE7G
CAS number
571190-30-2
Weight
Average: 447.5328
Monoisotopic: 447.238273207
Chemical Formula
C24H29N7O2
InChI Key
AHJRHEGDXFFMBM-UHFFFAOYSA-N
InChI
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
IUPAC Name
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H,8H-pyrido[2,3-d]pyrimidin-7-one
SMILES
CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N3CCNCC3)N=C2N(C2CCCC2)C1=O

Pharmacology

Indication

Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Structured Indications
Pharmacodynamics

Treatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb) phosphorylation resulting in reduced E2F expression and signaling and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens leads to increased cell senescence, which was sustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drug alone.

Mechanism of action

Palbociclib is an oral, reversible, selective, small-molecule inhibitor of CDK4 and CDK6. CDK4 and CDK6 along with their regulatory partner cyclin D1 play a key role in regulating the G1- to S-phase cell-cycle transition via regulation of phosphorylation of the retinoblastoma (Rb) protein.

TargetActionsOrganism
ACyclin-dependent kinase 4
inhibitor
Human
ACyclin-dependent kinase 6
inhibitor
Human
Absorption

The mean Cmax of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration. The mean absolute bioavailability after an oral 125 mg dose is 46%.

Volume of distribution

The mean apparent distribution of palbociclib is 2583 L, suggesting that palbociclib penetrates extensively into peripheral tissues.

Protein binding

Binding of palbociclib to human plasma proteins in vitro is approximately 85%.

Metabolism

The primary metabolic pathways for palbociclib involve oxidation and sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib is the major circulating drug-derived entity in plasma (23%). The major circulating metabolite was found to be a glucuronide conjugate of palbociclib, although it only represented 1.5% of the administered dose in the excreta.

Route of elimination

Palbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose.

Half life

The mean plasma elimination half-life is 29 hours.

Clearance

63.1 L/hr

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Palbociclib.Approved
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Palbociclib.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Palbociclib.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Palbociclib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Palbociclib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Palbociclib.Experimental
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Palbociclib.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Palbociclib.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Palbociclib.Approved
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Palbociclib.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Palbociclib.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Palbociclib.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Palbociclib.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Palbociclib.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Palbociclib.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Palbociclib.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Palbociclib.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Palbociclib.Approved, Investigational
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Palbociclib.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Palbociclib.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Palbociclib.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Palbociclib.Approved
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Palbociclib.Approved
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Palbociclib.Approved
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Palbociclib.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Palbociclib.Approved
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Palbociclib.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Palbociclib.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Palbociclib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Palbociclib.Approved
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Palbociclib.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Palbociclib.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Palbociclib.Approved, Investigational
AtomoxetineThe metabolism of Palbociclib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Palbociclib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Palbociclib.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Palbociclib.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Palbociclib.Approved
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Palbociclib.Approved
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Palbociclib.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Palbociclib.Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Palbociclib.Approved
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Palbociclib.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Palbociclib.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Palbociclib.Approved, Investigational
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Palbociclib.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Palbociclib.Approved
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Palbociclib.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Palbociclib.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Palbociclib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Palbociclib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Palbociclib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Palbociclib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Palbociclib.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Palbociclib.Approved
BrivaracetamThe serum concentration of Brivaracetam can be increased when it is combined with Palbociclib.Approved, Investigational
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Palbociclib.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Palbociclib.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Palbociclib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Palbociclib.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Palbociclib.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Palbociclib.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Palbociclib.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Palbociclib.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Palbociclib.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Palbociclib.Approved
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Palbociclib.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Palbociclib.Approved
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Palbociclib.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Palbociclib.Approved, Investigational
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Palbociclib.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Palbociclib.Approved, Vet Approved
CeritinibThe serum concentration of Palbociclib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Palbociclib.Withdrawn
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Palbociclib.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Palbociclib.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Palbociclib.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Palbociclib.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Palbociclib.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Palbociclib.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Palbociclib.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Palbociclib.Approved
ClemastineThe metabolism of Palbociclib can be decreased when combined with Clemastine.Approved
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Palbociclib.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Palbociclib.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Palbociclib.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Palbociclib.Approved, Investigational
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Palbociclib.Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Palbociclib.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Palbociclib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Palbociclib.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Palbociclib.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.Approved
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Palbociclib.Approved, Illicit
ClotrimazoleThe metabolism of Palbociclib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Palbociclib.Approved
CobicistatThe serum concentration of Palbociclib can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Cocaine can be increased when it is combined with Palbociclib.Approved, Illicit
CodeineThe serum concentration of Codeine can be increased when it is combined with Palbociclib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Palbociclib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Palbociclib.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Palbociclib.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Palbociclib.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Palbociclib.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Palbociclib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Palbociclib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Palbociclib.Experimental
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Palbociclib.Approved, Investigational
DabrafenibThe serum concentration of Palbociclib can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Palbociclib.Approved
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.Approved
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Palbociclib.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Palbociclib.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Palbociclib.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Palbociclib.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Palbociclib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Palbociclib.Approved
DeferasiroxThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Palbociclib.Approved
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Palbociclib.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Palbociclib.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Palbociclib.Approved
DeutetrabenazineThe serum concentration of Deutetrabenazine can be increased when it is combined with Palbociclib.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe serum concentration of Dexchlorpheniramine maleate can be increased when it is combined with Palbociclib.Approved
DexlansoprazoleThe serum concentration of Dexlansoprazole can be increased when it is combined with Palbociclib.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Palbociclib.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Palbociclib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Palbociclib.Approved, Vet Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Palbociclib.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Palbociclib.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Palbociclib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Palbociclib.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Palbociclib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Palbociclib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Palbociclib.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Palbociclib.Experimental
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Palbociclib.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Palbociclib.Approved
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Palbociclib.Approved
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Palbociclib.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Palbociclib.Approved
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Palbociclib.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Palbociclib.Approved
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Palbociclib.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Palbociclib.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Palbociclib.Approved, Investigational
DoxycyclineThe metabolism of Palbociclib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Palbociclib.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Palbociclib.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Palbociclib.Approved, Investigational
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Palbociclib.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Palbociclib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Palbociclib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Palbociclib.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Palbociclib.Approved
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Palbociclib.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Palbociclib.Approved
EnzalutamideThe serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Palbociclib.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Palbociclib.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Palbociclib.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Palbociclib.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Palbociclib.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Palbociclib.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Palbociclib.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Palbociclib.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Palbociclib.Approved, Investigational
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Palbociclib.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be increased when it is combined with Palbociclib.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Palbociclib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Palbociclib.Approved
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Palbociclib.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Palbociclib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Palbociclib.Approved
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Palbociclib.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Palbociclib.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Palbociclib.Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Palbociclib.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Palbociclib.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Palbociclib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Palbociclib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.Approved
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Palbociclib.Approved, Investigational
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Palbociclib.Approved
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Palbociclib.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Palbociclib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Palbociclib.Approved
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Palbociclib.Approved
FingolimodPalbociclib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.Approved
FluconazoleThe metabolism of Palbociclib can be decreased when combined with Fluconazole.Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Palbociclib.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Palbociclib.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Palbociclib.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.Approved, Vet Approved
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Palbociclib.Approved, Illicit
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Palbociclib.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Palbociclib.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Palbociclib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Palbociclib.Approved
FluvoxamineThe metabolism of Palbociclib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Palbociclib.Approved
FosaprepitantThe serum concentration of Palbociclib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Palbociclib can be decreased when it is combined with Fosphenytoin.Approved
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Palbociclib.Approved, Investigational
Fusidic AcidThe serum concentration of Palbociclib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Palbociclib.Investigational
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Palbociclib.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Palbociclib.Approved
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Palbociclib.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Palbociclib.Experimental
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Palbociclib.Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Palbociclib.Approved
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Palbociclib.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Palbociclib.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Palbociclib.Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Palbociclib.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Palbociclib.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Palbociclib.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Palbociclib.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Palbociclib.Approved, Withdrawn
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Palbociclib.Approved
HistamineThe serum concentration of Histamine can be increased when it is combined with Palbociclib.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Palbociclib.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Palbociclib.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Palbociclib.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Palbociclib.Approved
IcotinibThe serum concentration of Icotinib can be increased when it is combined with Palbociclib.Approved, Investigational
IdelalisibThe serum concentration of Palbociclib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Palbociclib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Palbociclib.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Palbociclib.Approved, Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Palbociclib.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Palbociclib.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Palbociclib.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Palbociclib.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Palbociclib.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Palbociclib.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Palbociclib.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.Approved
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Palbociclib.Approved
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Palbociclib.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Palbociclib.Approved
IvacaftorThe serum concentration of Palbociclib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Palbociclib.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Palbociclib.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Palbociclib.Approved
KetamineThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Palbociclib.Approved
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Palbociclib.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Palbociclib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Palbociclib.Experimental
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Palbociclib.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Palbociclib.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Palbociclib.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Palbociclib is combined with Leflunomide.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Palbociclib.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Palbociclib.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Palbociclib.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Palbociclib.Approved, Investigational
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Palbociclib.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Palbociclib.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Palbociclib.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Palbociclib.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Palbociclib.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Palbociclib.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be increased when it is combined with Palbociclib.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Palbociclib.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Palbociclib.Approved
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Palbociclib.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Palbociclib.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Palbociclib.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Palbociclib.Approved, Investigational
LuliconazoleThe serum concentration of Palbociclib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Palbociclib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Palbociclib.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Palbociclib.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Palbociclib.Illicit, Investigational, Withdrawn
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Palbociclib.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Palbociclib.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Palbociclib.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.Approved, Investigational
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Palbociclib.Approved
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Palbociclib.Approved, Vet Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Palbociclib.Experimental
MethadoneThe serum concentration of Methadone can be increased when it is combined with Palbociclib.Approved
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Palbociclib.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Palbociclib.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Palbociclib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Palbociclib.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Palbociclib.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Palbociclib.Experimental
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Palbociclib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Palbociclib.Experimental
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Palbociclib.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Palbociclib.Approved, Investigational
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Palbociclib.Investigational, Withdrawn
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.Approved, Illicit
MidostaurinThe serum concentration of Midostaurin can be increased when it is combined with Palbociclib.Approved
MifepristoneThe serum concentration of Palbociclib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.Approved
MitotaneThe serum concentration of Palbociclib can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Palbociclib.Approved, Investigational
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Palbociclib.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Palbociclib.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Palbociclib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Palbociclib.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Palbociclib.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Palbociclib.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Palbociclib.Approved
NeratinibThe serum concentration of Neratinib can be increased when it is combined with Palbociclib.Approved, Investigational
NetupitantThe serum concentration of Palbociclib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Palbociclib.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Palbociclib.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Palbociclib.Approved, Investigational
NicotineThe serum concentration of Nicotine can be increased when it is combined with Palbociclib.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Palbociclib.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Palbociclib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Palbociclib.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.Approved
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Palbociclib.Approved
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Palbociclib.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Palbociclib.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Palbociclib.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Palbociclib.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Palbociclib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Palbociclib.Experimental, Investigational
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.Approved
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Palbociclib.Approved
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Palbociclib.Approved
OsimertinibThe serum concentration of Palbociclib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Palbociclib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Palbociclib.Approved
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Palbociclib.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Palbociclib.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Palbociclib.Approved, Vet Approved
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Palbociclib.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Palbociclib.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Palbociclib.Approved
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Palbociclib.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Palbociclib.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Palbociclib.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Palbociclib.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Palbociclib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Palbociclib.Approved
PergolideThe serum concentration of Pergolide can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Palbociclib.Approved, Investigational
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Palbociclib.Approved, Investigational
PerospironeThe serum concentration of Perospirone can be increased when it is combined with Palbociclib.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Palbociclib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Palbociclib.Experimental
PethidineThe serum concentration of Pethidine can be increased when it is combined with Palbociclib.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Palbociclib.Withdrawn
PhenobarbitalThe serum concentration of Palbociclib can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Palbociclib.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Palbociclib.Approved, Investigational
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Palbociclib.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Palbociclib.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Palbociclib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Palbociclib.Approved
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Palbociclib.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Palbociclib.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Palbociclib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Palbociclib.Approved
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Palbociclib.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Palbociclib.Approved
PosaconazoleThe serum concentration of Posaconazole can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be increased when it is combined with Palbociclib.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Palbociclib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Palbociclib.Approved
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Palbociclib.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Palbociclib.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Palbociclib.Approved
PrimidoneThe serum concentration of Palbociclib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Palbociclib.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Propoxyphene napsylate can be increased when it is combined with Palbociclib.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Palbociclib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Palbociclib.Experimental
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Palbociclib.Approved
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Palbociclib.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.Approved
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Palbociclib.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Palbociclib.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Palbociclib.Approved
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Palbociclib.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Palbociclib is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Palbociclib.Approved
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Palbociclib.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Palbociclib.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Palbociclib.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Palbociclib.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Palbociclib.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Palbociclib.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Palbociclib.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Palbociclib.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Palbociclib.Approved
RifapentineThe serum concentration of Palbociclib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Palbociclib.Approved
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Palbociclib.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Palbociclib.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Palbociclib.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Palbociclib.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Palbociclib.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Palbociclib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Palbociclib.Approved
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Palbociclib.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Palbociclib.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Palbociclib.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Palbociclib.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Palbociclib.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Palbociclib.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Palbociclib.Approved
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Palbociclib.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Palbociclib.Approved, Investigational
RupatadineThe serum concentration of Rupatadine can be increased when it is combined with Palbociclib.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Palbociclib.Approved
SafinamideThe serum concentration of Safinamide can be increased when it is combined with Palbociclib.Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Palbociclib.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Palbociclib.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Palbociclib.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Palbociclib.Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Palbociclib.Approved
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Palbociclib.Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Palbociclib.Approved
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Palbociclib.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.Approved
SiltuximabThe serum concentration of Palbociclib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Palbociclib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Palbociclib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Palbociclib.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Palbociclib.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Palbociclib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Palbociclib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Palbociclib.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Palbociclib.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Palbociclib.Investigational
St. John's WortThe serum concentration of Palbociclib can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Palbociclib can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Palbociclib.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Palbociclib.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Palbociclib.Approved
SulfisoxazoleThe metabolism of Palbociclib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Palbociclib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Palbociclib.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Palbociclib.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Palbociclib.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Palbociclib.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Palbociclib.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Palbociclib.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Palbociclib.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Palbociclib.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Palbociclib.Investigational
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Palbociclib.Approved, Withdrawn
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Palbociclib.Approved
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Palbociclib.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Palbociclib.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Palbociclib.Approved
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Palbociclib.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Palbociclib.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Palbociclib.Experimental
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Palbociclib.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Palbociclib.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Palbociclib.Approved, Vet Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Palbociclib.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Palbociclib.Approved
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Palbociclib.Approved
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Palbociclib.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Palbociclib.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Palbociclib.Approved
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Palbociclib.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Palbociclib.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Palbociclib.Approved, Investigational
TocilizumabThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Palbociclib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Palbociclib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Palbociclib.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Palbociclib.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Palbociclib.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Palbociclib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Palbociclib.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Palbociclib.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Palbociclib.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Palbociclib.Approved
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Palbociclib.Approved
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Palbociclib.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Palbociclib.Approved
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Palbociclib.Investigational, Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Palbociclib.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Palbociclib.Approved, Experimental
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Palbociclib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Palbociclib.Approved
ValbenazineThe serum concentration of Valbenazine can be increased when it is combined with Palbociclib.Approved, Investigational
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Palbociclib.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Palbociclib.Approved
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Palbociclib.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Palbociclib.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Palbociclib.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Palbociclib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Palbociclib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Palbociclib.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.Approved
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Palbociclib.Investigational
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Palbociclib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Palbociclib.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Palbociclib.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Palbociclib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Palbociclib.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Palbociclib.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Palbociclib.Approved
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Palbociclib.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Palbociclib.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Palbociclib.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Palbociclib.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Palbociclib.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Palbociclib.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Palbociclib.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Palbociclib.Approved, Investigational
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Palbociclib.Approved, Illicit, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Palbociclib.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Palbociclib.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Palbociclib.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Palbociclib.Approved
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Palbociclib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Palbociclib.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Palbociclib.Approved
Food Interactions
Not Available

References

General References
  1. Dhillon S: Palbociclib: first global approval. Drugs. 2015 Apr;75(5):543-51. doi: 10.1007/s40265-015-0379-9. [PubMed:25792301]
  2. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782]
  3. Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF: PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013 Aug;33(8):2997-3004. [PubMed:23898052]
  4. Authors unspecified: Palbociclib Extends Survival in Advanced Breast Cancer. Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2. [PubMed:26036642]
  5. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M: Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1. [PubMed:26030518]
  6. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. doi: 10.1016/S1470-2045(14)71159-3. Epub 2014 Dec 16. [PubMed:25524798]
  7. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. [PubMed:25501126]
External Links
KEGG Drug
D10372
PubChem Compound
5330286
PubChem Substance
310265004
ChemSpider
4487437
BindingDB
6309
ChEBI
85993
ChEMBL
CHEMBL189963
PharmGKB
PA166153469
HET
LQQ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Palbociclib
ATC Codes
L01XE33 — Palbociclib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
2euf / 5l2i
FDA label
Download (481 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherAdvanced Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumor Malignancies1
1Active Not RecruitingTreatmentCancer, Breast1
1Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentRecurrent Mantle Cell Lymphoma / T(11;14)1
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceHealthy, Hepatic Insufficiency1
1CompletedBasic ScienceImpaired Renal Function1
1CompletedTreatmentCancers1
1CompletedTreatmentLymphoma, Mantle-Cell1
1CompletedTreatmentNeoplasms / Non-Hodgkin's Lymphoma (NHL)1
1Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentAdvanced Breast Cancer1
1RecruitingTreatmentAdvanced Solid Tumours / Cancer, Breast1
1RecruitingTreatmentBladder Cancers / Cancer of Unknown Primary / Cancer, Ovarian / Colorectal Cancers / Head and Neck Carcinoma / Sarcomas / Solid Neoplasms / Stage III Pancreatic Cancer / Stage IIIA Breast Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Breast Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IVA Pancreatic Cancer / Stage IVB Pancreatic Cancer1
1RecruitingTreatmentCancer, Breast3
1RecruitingTreatmentCancer, Breast / Tumors, Solid1
1RecruitingTreatmentChildhood Choroid Plexus Tumor / Childhood Ependymoblastoma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Recurrent Childhood Anaplastic Astrocytoma / Recurrent Childhood Anaplastic Oligoastrocytoma / Recurrent Childhood Anaplastic Oligodendroglioma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Giant Cell Glioblastoma / Recurrent Childhood Glioblastoma / Recurrent Childhood Gliomatosis Cerebri / Recurrent Childhood Gliosarcoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
1RecruitingTreatmentHead & Neck Cancer / Lung Cancer Squamous Cell / Malignant Neoplasm of Pancreas / Tumors, Solid1
1RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Neoplasms of Uncertain or Unknown Behavior1
1RecruitingTreatmentMetastatic Pancreatic Ductal Adenocarcinoma1
1TerminatedTreatmentHigh-Risk Myelodysplasia / Refractory Acute Leukemia / Relapsed Acute Leukemia1
1TerminatedTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentKRAS Mutant Non-Small Cell Lung Cancer / Tumors, Solid1
1, 2Not Yet RecruitingTreatmentBreast Diseases / Neoplasms, Breast1
1, 2Not Yet RecruitingTreatmentCancer, Breast1
1, 2Not Yet RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Negative / Invasive Breast Carcinoma / Multifocal Breast Carcinoma / One to five years postmenopausal / Progesterone Receptor Positive / Stage I Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2Not Yet RecruitingTreatmentGlioblastoma, Adult1
1, 2Not Yet RecruitingTreatmentHead and Neck Carcinoma / Locally Advanced / Unresectable1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentAdvanced and Metastatic Breast Cancer1
1, 2RecruitingTreatmentBreast Cancer Metastatic / Metastatic Invasive Breast Cancer / Unresectable Locally Advanced Invasive Breast Cancer1
1, 2RecruitingTreatmentCDNKN2A Loss Defined / Melanoma BRAF V600E/K Mutated1
1, 2RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
1, 2RecruitingTreatmentHormone Receptor (HR)-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
1, 2RecruitingTreatmentLung Cancers1
1, 2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingNot AvailableNeoplasms, Breast1
2Active Not RecruitingTreatmentAdvanced Gastrointestinal Stromal Tumors1
2Active Not RecruitingTreatmentAdvanced Hepatocellular Carcinoma / HCC / Liver Cancer1
2Active Not RecruitingTreatmentCancer, Breast5
2Active Not RecruitingTreatmentNeoadjuvant Operable Breast Cancer1
2Active Not RecruitingTreatmentNeoplasms / Neoplasms, Breast1
2Active Not RecruitingTreatmentOvarian Epithelial Carcinoma1
2Active Not RecruitingTreatmentPancreatic Neuroendocrine Cancer1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentLiposarcoma / Sarcomas1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentUntreated Operable Early Breast Cancer1
2Not Yet RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentCancer, Advanced1
2Not Yet RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Not Yet RecruitingTreatmentChordomas1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentThymic Cancer1
2RecruitingBasic ScienceCancer, Breast1
2RecruitingTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Adult Central Nervous System Germ Cell Tumor / Adult Solid Tumor / Adult Teratoma / Benign Teratoma / Estrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Familial Testicular Germ Cell Tumor / HER2-Negative Breast Cancer / Her2-Positive Breast Cancer / Male Breast Cancer / Ovarian Immature Teratoma / Ovarian Mature Teratoma / Ovarian Monodermal and Highly Specialized Teratoma / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Recurrent Colon Cancer / Recurrent Extragonadal Germ Cell Tumor / Recurrent Extragonadal Non-seminomatous Germ Cell Tumor / Recurrent Extragonadal Seminoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Melanoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Rectal Cancer / Stage III Extragonadal Non-seminomatous Germ Cell Tumor / Stage III Extragonadal Seminoma / Stage III Malignant Testicular Germ Cell Tumor / Stage III Ovarian Germ Cell Tumor / Stage IV Breast Cancer / Stage IV Colon Cancer / Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor / Stage IV Extragonadal Seminoma / Stage IV Melanoma / Stage IV Ovarian Germ Cell Tumor / Stage IV Rectal Cancer / Testicular Immature Teratoma / Testicular Mature Teratoma1
2RecruitingTreatmentAdenocarcinomas / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdvanced Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Bladder Carcinoma / Carcinoma, Breast / Carcinoma, Colorectal / Carcinoma, Pancreatic / Cervical Carcinoma / Colon Carcinoma / Endometrial Carcinoma / Gastric Carcinoma / Gliomas / Head and Neck Carcinoma / Liver and Intrahepatic Bile Duct Carcinoma / Lung, Carcinoma / Malignant Lymphomas / Malignant Uterine Neoplasm / Melanoma / Oesophageal Carcinoma / Ovarian Carcinoma / Plasma Cell Myeloma / Prostate Cancer / Rectal Carcinoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Cervical Carcinoma / Recurrent Colon Carcinoma / Recurrent Colorectal Carcinoma / Recurrent Esophageal Carcinoma / Recurrent Gastric Carcinoma / Recurrent Gliomas / Recurrent Head and Neck Carcinoma / Recurrent Liver Carcinoma / Recurrent Lung Carcinoma / Recurrent Lymphoma / Recurrent Malignant Solid Neoplasm / Recurrent Melanoma / Recurrent Ovarian Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Plasma Cell Myeloma / Recurrent Prostate Carcinoma / Recurrent Rectal Carcinoma / Recurrent Skin Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Uterine Corpus Carcinoma / Refractory Lymphomas / Refractory Malignant Neoplasm / Refractory Malignant Solid Neoplasm / Refractory Plasma Cell Myeloma / Renal Carcinoma / Skin Carcinoma / Solid Neoplasms / Thyroid Gland Carcinoma / Uterine Corpus Cancer1
2RecruitingTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentBreast Cancer Metastatic1
2RecruitingTreatmentBreast Carcinoma Metastatic in the Brain / Estrogen Receptor Negative / HER2/Neu Negative / HER2/Neu Positive / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentCancer of Breast / Cancer, Breast / Carcinoma, Breast1
2RecruitingTreatmentCancer of Breast / Cancer, Breast / Carcinoma, Breast / Malignant Tumor of Breast1
2RecruitingTreatmentCancer, Advanced / Sarcomas1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancer, Breast / Carcinoma, Breast / Tumors, Breast1
2RecruitingTreatmentCancer, Breast / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2RecruitingTreatmentEarly-Stage Breast Carcinoma / Estrogen Receptor Positive Tumor1
2RecruitingTreatmentEarly-Stage Breast Carcinoma / Hormone Receptor Positive Tumor1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentEstrogen Receptor Positive Breast Cancer / Hormone Receptor Positive Malignant Neoplasm of Breast / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Breast Cancer (MBC) / Progesterone Receptor Positive Tumor1
2RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Negative / One to five years postmenopausal / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
2RecruitingTreatmentEstrogen Receptor and/or Progesterone Receptor Positive / HER2/Neu Negative / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2RecruitingTreatmentFemale Breast Carcinoma1
2RecruitingTreatmentHormone Receptor Positive / Metastatic Breast Cancer (MBC)1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2RecruitingTreatmentMalignant Neoplasm of Female Breast1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)7
2RecruitingTreatmentMetastatic Malignant Neoplasm to Brain1
2RecruitingTreatmentNeoplasms, Breast2
2RecruitingTreatmentOligoastrocytoma / Oligodendrogliomas1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentRare Tumor / Refractory Tumors1
2RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)2
2TerminatedTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas / Gliosarcoma1
2TerminatedTreatmentMetastatic Urothelial Carcinoma (UC)1
2, 3Active Not RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentNeoplasms, Breast1
3No Longer AvailableNot AvailableAdvanced Breast Cancer (Female)1
3RecruitingTreatmentAdvanced Breast Cancer (Female) / Advanced Breast Cancer Female1
3RecruitingTreatmentCancer, Breast / CPS-EG Score / Her2-normal / Hormonreceptor Positive / Postneoadjuvant Treatment With CDK 4/6 Inhibitor1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentEstrogen Receptor Positive Breast Cancer / HER-2 Positive Breast Cancer1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)2
3RecruitingTreatmentNeoplasms, Breast1
4RecruitingTreatmentCancer, Breast1
Not AvailableCompletedNot AvailableAdvanced Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Breast Cancer (MBC)1
Not AvailableRecruitingNot AvailableMalignant Neoplasm of Breast1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral125 mg/1
CapsuleOral125 mg
CapsuleOral75 mg
CapsuleOral75 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7456168No2003-01-162023-01-16Us
US6936612No2003-01-222023-01-22Us
US7208489No2003-01-162023-01-16Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa7.4 (the secondary piperazine nitrogen) and 3.9 (the pyridine nitrogen)FDA Label
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP2.12ALOGPS
logP2.77ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)11.34ChemAxon
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area103.35 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127.47 m3·mol-1ChemAxon
Polarizability49.69 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Pyridinylpiperazines
Alternative Parents
N-arylpiperazines / Pyrido[2,3-d]pyrimidines / Aryl alkyl ketones / Dialkylarylamines / Pyridinones / Aminopyridines and derivatives / Aminopyrimidines and derivatives / Methylpyridines / Imidolactams / Vinylogous amides
show 7 more
Substituents
N-arylpiperazine / Pyridinylpiperazine / Pyridopyrimidine / Pyrido[2,3-d]pyrimidine / Tertiary aliphatic/aromatic amine / Aryl ketone / Aryl alkyl ketone / Dialkylarylamine / Aminopyrimidine / Aminopyridine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, tertiary amino compound, secondary amino compound, ring assembly, aromatic ketone, cyclopentanes, pyridopyrimidine, aminopyridine (CHEBI:85993)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Cyclin-dependent protein serine/threonine kinase regulator activity
Specific Function
Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S tra...
Gene Name
CDK4
Uniprot ID
P11802
Uniprot Name
Cyclin-dependent kinase 4
Molecular Weight
33729.55 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Cyclin-dependent protein serine/threonine kinase activity
Specific Function
Serine/threonine-protein kinase involved in the control of the cell cycle and differentiation; promotes G1/S transition. Phosphorylates pRB/RB1 and NPM1. Interacts with D-type G1 cyclins during int...
Gene Name
CDK6
Uniprot ID
Q00534
Uniprot Name
Cyclin-dependent kinase 6
Molecular Weight
36938.025 Da
References
  1. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38. [PubMed:15542782]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
2. Sulfotransferase 2A1
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate

Drug created on May 14, 2015 14:03 / Updated on November 22, 2017 12:38